Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society
Andrea M. Yeung, Jingtong Huang, Ambarish Pandey, Ibrahim A. Hashim, David Kerr, Rodica Pop‐Busui, Connie M. Rhee, Viral N. Shah, Lia Bally, Antoni Bayés‐Genís, Yong Mong Bee, Richard M. Bergenstal, Javed Butler, G. Alexander Fleming, Gregory H. Gilbert, Stephen J. Greene, Mikhail Kosiborod, Lawrence A. Leiter, Boris Mankovsky, Thomas W. Martens, Chantal Mathieu, Viswanathan Mohan, Kershaw V. Patel, Anne L. Peters, Eun‐Jung Rhee, Giuseppe Rosano, David B. Sacks, Yader Sandoval, Jane Jeffrie Seley, Oliver Schnell, Guillermo E. Umpierrez, Kayo Waki, Eugene E. Wright, Alan H.B. Wu, David C. Klonoff
Abstract
Diabetes Technology Society assembled a panel of clinician experts in diabetology, cardiology, clinical chemistry, nephrology, and primary care to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF), who are, by definition, at risk for HF (Stage A HF). This consensus report reviews features of HF in PWD from the perspectives of 1) epidemiology, 2) classification of stages, 3) pathophysiology, 4) biomarkers for diagnosing, 5) biomarker assays, 6) diagnostic accuracy of biomarkers, 7) benefits of biomarker screening, 8) consensus recommendations for biomarker screening, 9) stratification of Stage B HF, 10) echocardiographic screening, 11) management of Stage A and Stage B HF, and 12) future directions. The Diabetes Technology Society panel recommends 1) biomarker screening with one of two circulating natriuretic peptides (B-type natriuretic peptide or N-terminal prohormone of B-type natriuretic peptide), 2) beginning screening five years following diagnosis of type 1 diabetes (T1D) and at the diagnosis of type 2 diabetes (T2D), 3) beginning routine screening no earlier than at age 30 years for T1D (irrespective of age of diagnosis) and at any age for T2D, 4) screening annually, and 5) testing any time of day. The panel also recommends that an abnormal biomarker test defines asymptomatic preclinical HF (Stage B HF). This diagnosis requires follow-up using transthoracic echocardiography for classification into one of four subcategories of Stage B HF, corresponding to risk of progression to symptomatic clinical HF (Stage C HF). These recommendations will allow identification and management of Stage A and Stage B HF in PWD to prevent progression to Stage C HF or advanced HF (Stage D HF).